Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyPentazocine
Identification
- Name
- Pentazocine
- Accession Number
- DB00652 (APRD01173)
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Description
The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
- Structure
Structure for DB00652 (Pentazocine)
- Synonyms
- Pentazocin
- Pentazocina
- Pentazocine
- Pentazocinum
- External IDs
- CS 350 / NIH 7958 / Win 20228
- Product Ingredients
Ingredient UNII CAS InChI Key Pentazocine Hydrochloride A36BXO4PPX 64024-15-3 OQGYMIIFOSJQSF-DTOXXUQYSA-N Pentazocine Lactate 1P2XIB510O 17146-95-1 QNLDTXPVZPRSAM-DTOXXUQYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Talwin Injection, solution 30 mg/mL Intramuscular; Intravenous; Subcutaneous General Injectables & Vaccines 2010-08-01 2017-01-25 US 
Talwin Injection, solution 30 mg/mL Intramuscular; Intravenous; Subcutaneous Hospira, Inc. 2005-11-18 2018-04-10 US Talwin Injection, solution 30 mg/mL Intramuscular; Intravenous; Subcutaneous Hospira, Inc. 2010-10-12 2017-08-11 US Talwin Tablet 50 mg Oral Sanofi Aventis 1970-12-31 Not applicable Canada 
Talwin Solution 30 mg Intramuscular; Intravenous; Subcutaneous Pfizer 2002-11-01 Not applicable Canada Talwin - Liq 30mg/ml Liquid 30 mg Intramuscular; Intravenous; Subcutaneous Sanofi Synthelabo 1967-12-31 Not applicable Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Pentazocine and naloxone Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1) Tablet Oral Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc 1997-01-21 2017-09-21 US Pentazocine and Naloxone Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1) Tablet Oral Golden State Medical Supply 2000-03-24 Not applicable US Pentazocine and naloxone Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1) Tablet Oral Actavis Pharma Company 1997-01-21 Not applicable US Pentazocine and naloxone Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1) Tablet Oral Keltman Pharmaceuticals Inc. 2009-07-21 Not applicable US Pentazocine and naloxone Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1) Tablet Oral Pd Rx Pharmaceuticals, Inc. 1997-01-21 Not applicable US Pentazocine and naloxone Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1) Tablet Oral bryant ranch prepack 1997-01-21 2018-06-07 US Pentazocine and Naloxone Pentazocine (50 mg/1) + Naloxone hydrochloride (.5 mg/1) Tablet Oral Sun Pharmaceutical Industries Limited 2018-06-29 Not applicable US Pentazocine HCl and Acetaminophen Pentazocine Hydrochloride (25 mg/1) + Acetaminophen (650 mg/1) Tablet Oral Rebel Distributors 2000-03-24 Not applicable US Pentazocine HCl and Naloxone HCl Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1) Tablet Oral Stat Rx USA 1997-01-21 2018-02-08 US Pentazocine Hydrochloride and Acetaminophen Pentazocine Hydrochloride (25 mg/1) + Acetaminophen (650 mg/1) Tablet Oral Gavis Pharmaceuticals, LLC. 2011-05-11 Not applicable US - International/Other Brands
- Fortal (Sanofi-Aventis) / Fortral (Sanofi-Aventis) / Fortwin (Terapia) / Pangon (L.B.S.) / Pentagin (Daiichi Sankyo) / Sosegon (Sanofi-Aventis) / Stopain (Beximco) / Talwin PX (Sanofi-Aventis)
- Categories
- Adjuvants, Anesthesia
- Alkaloids
- Analgesics
- Benzomorphan Derivatives
- Benzomorphans
- Central Nervous System Agents
- Central Nervous System Depressants
- Mixed Agonist / Antagonist Opioids
- Morphinans
- Narcotics
- Nervous System
- Opiate Alkaloids
- Opiate Partial Agonists
- Opioid Antagonists
- Opioids
- P-glycoprotein/ABCB1 Inhibitors
- P-glycoprotein/ABCB1 Substrates
- Partial Opioid Agonist/Antagonist
- Peripheral Nervous System Agents
- Phenanthrenes
- Sensory System Agents
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- UNII
- 768DQ5A5AI
- CAS number
- 359-83-1
- Weight
- Average: 285.4238
Monoisotopic: 285.209264491 - Chemical Formula
- C19H27NO
- InChI Key
- VOKSWYLNZZRQPF-GDIGMMSISA-N
- InChI
- InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1
- IUPAC Name
- (1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0²,⁷]trideca-2,4,6-trien-4-ol
- SMILES
- C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C
Pharmacology
- Indication
For the relief of moderate to severe pain.
- Associated Conditions
- Associated Therapies
- Pharmacodynamics
Pentazocine is a potent analgesic which when administered orally in a 50 mg dose appears equivalent in analgesic effect to 60 mg (1 grain) of codeine. Onset of significant analgesia usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer. Onset and duration of action and the degree of pain relief are related both to dose and the severity of pretreatment pain. Pentazocine weakly antagonizes the analgesic effects of morphine and meperidine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.
- Mechanism of action
The preponderance of evidence suggests that pentazocine antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor.
Target Actions Organism AMu-type opioid receptor antagonistHuman AKappa-type opioid receptor agonistHuman ASigma non-opioid intracellular receptor 1 agonistHuman - Absorption
Well absorbed from the gastro-intestinal tract.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Hepatic
- Route of elimination
- Not Available
- Half life
2 to 3 hours
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Pentazocine Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Pentazocine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Pentazocine. Experimental 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pentazocine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pentazocine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Pentazocine is combined with 7-Nitroindazole. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when Pentazocine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. Experimental Acepromazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Aceprometazine. Approved Acetazolamide The risk or severity of adverse effects can be increased when Pentazocine is combined with Acetazolamide. Approved, Vet Approved Aclidinium The risk or severity of adverse effects can be increased when Aclidinium is combined with Pentazocine. Approved Adipiplon The risk or severity of adverse effects can be increased when Pentazocine is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Pentazocine is combined with Agomelatine. Approved, Investigational Alaproclate Pentazocine may increase the serotonergic activities of Alaproclate. Experimental Alcuronium The risk or severity of adverse effects can be increased when Alcuronium is combined with Pentazocine. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Pentazocine is combined with Alfaxalone. Vet Approved Alfentanil Pentazocine may decrease the analgesic activities of Alfentanil. Approved, Illicit Alimemazine Alimemazine may increase the hypotensive activities of Pentazocine. Approved, Vet Approved Allopregnanolone The risk or severity of adverse effects can be increased when Pentazocine is combined with Allopregnanolone. Investigational Alphacetylmethadol Pentazocine may decrease the analgesic activities of Alphacetylmethadol. Experimental, Illicit Alphaprodine Pentazocine may decrease the analgesic activities of Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Pentazocine. Approved, Illicit, Investigational Alvimopan The risk or severity of adverse effects can be increased when Pentazocine is combined with Alvimopan. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Pentazocine is combined with Amiloride. Approved Amisulpride The risk or severity of adverse effects can be increased when Pentazocine is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Pentazocine is combined with Amitriptyline. Approved Ammonium chloride Ammonium chloride may increase the excretion rate of Pentazocine which could result in a lower serum level and potentially a reduction in efficacy. Approved, Investigational, Vet Approved Amobarbital The risk or severity of adverse effects can be increased when Pentazocine is combined with Amobarbital. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Pentazocine is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Pentazocine is combined with Amperozide. Experimental Amphetamine The risk or severity of adverse effects can be increased when Pentazocine is combined with Amphetamine. Approved, Illicit, Investigational Anisotropine Methylbromide The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pentazocine. Approved Aripiprazole The risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Pentazocine is combined with Asenapine. Approved Atracurium The risk or severity of adverse effects can be increased when Atracurium is combined with Pentazocine. Approved, Experimental, Investigational Atracurium besylate The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentazocine. Approved Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Pentazocine. Approved, Vet Approved Azaperone The risk or severity of adverse effects can be increased when Pentazocine is combined with Azaperone. Investigational, Vet Approved Azelastine Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azosemide The risk or severity of adverse effects can be increased when Pentazocine is combined with Azosemide. Investigational Baclofen The risk or severity of adverse effects can be increased when Pentazocine is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital. Illicit Benactyzine The risk or severity of adverse effects can be increased when Benactyzine is combined with Pentazocine. Withdrawn Bendroflumethiazide The risk or severity of adverse effects can be increased when Pentazocine is combined with Bendroflumethiazide. Approved Benmoxin The risk or severity of adverse effects can be increased when Pentazocine is combined with Benmoxin. Withdrawn Benperidol The risk or severity of adverse effects can be increased when Pentazocine is combined with Benperidol. Approved, Investigational Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Pentazocine. Approved Benzocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Benzocaine. Approved, Investigational Benzphetamine Benzphetamine may increase the analgesic activities of Pentazocine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Pentazocine is combined with Benzyl alcohol. Approved Bezitramide Pentazocine may decrease the analgesic activities of Bezitramide. Experimental, Illicit, Withdrawn Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Pentazocine. Approved, Investigational BL-1020 BL-1020 may increase the hypotensive activities of Pentazocine. Investigational Bornaprine The risk or severity of adverse effects can be increased when Bornaprine is combined with Pentazocine. Experimental Brexpiprazole The risk or severity of adverse effects can be increased when Pentazocine is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved Brofaromine The risk or severity of adverse effects can be increased when Pentazocine is combined with Brofaromine. Experimental Bromazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromazepam. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromisoval. Experimental Bromotheophylline The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromotheophylline. Approved Bromperidol The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Pentazocine is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Pentazocine is combined with Brotizolam. Approved, Investigational, Withdrawn Bumetanide The risk or severity of adverse effects can be increased when Pentazocine is combined with Bumetanide. Approved Bupivacaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Bupivacaine. Approved, Investigational Buprenorphine Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Pentazocine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Pentazocine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Pentazocine is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Pentazocine is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Pentazocine is combined with Butethal. Approved, Illicit Butorphanol Butorphanol may decrease the analgesic activities of Pentazocine. Approved, Illicit, Vet Approved Butylscopolamine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Pentazocine. Approved, Investigational, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Pentazocine is combined with Canertinib. Investigational Canrenoic acid The risk or severity of adverse effects can be increased when Pentazocine is combined with Canrenoic acid. Approved, Withdrawn Canrenone The risk or severity of adverse effects can be increased when Pentazocine is combined with Canrenone. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Pentazocine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Pentazocine is combined with Carbinoxamine. Approved Carfentanil Pentazocine may decrease the analgesic activities of Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Pentazocine is combined with Carisoprodol. Approved Caroxazone The risk or severity of adverse effects can be increased when Pentazocine is combined with Caroxazone. Withdrawn Cetirizine The risk or severity of adverse effects can be increased when Pentazocine is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Pentazocine is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pentazocine. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Chloroprocaine. Approved Chlorothiazide The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide. Approved, Vet Approved Chlorphenamine The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorphenamine. Approved Chlorphenoxamine The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pentazocine. Withdrawn Chlorphentermine Chlorphentermine may increase the analgesic activities of Pentazocine. Illicit, Withdrawn Chlorproethazine Chlorproethazine may increase the hypotensive activities of Pentazocine. Experimental Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pentazocine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorthalidone The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorthalidone. Approved Chlorzoxazone The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorzoxazone. Approved Cicletanine The risk or severity of adverse effects can be increased when Pentazocine is combined with Cicletanine. Investigational Cinchocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Cinchocaine. Approved, Vet Approved Citalopram Pentazocine may increase the serotonergic activities of Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Pentazocine is combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Pentazocine is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Pentazocine is combined with Clobazam. Approved, Illicit Clofenamide The risk or severity of adverse effects can be increased when Pentazocine is combined with Clofenamide. Experimental clomethiazole The risk or severity of adverse effects can be increased when Pentazocine is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Pentazocine is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Pentazocine is combined with Clonidine. Approved Clopamide The risk or severity of adverse effects can be increased when Pentazocine is combined with Clopamide. Experimental Clopenthixol The risk or severity of adverse effects can be increased when Pentazocine is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Pentazocine. Approved, Illicit Clorexolone The risk or severity of adverse effects can be increased when Pentazocine is combined with Clorexolone. Experimental Clothiapine The risk or severity of adverse effects can be increased when Pentazocine is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Pentazocine. Approved Cocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Cocaine. Approved, Illicit Codeine Pentazocine may decrease the analgesic activities of Codeine. Approved, Illicit Conivaptan The risk or severity of adverse effects can be increased when Pentazocine is combined with Conivaptan. Approved, Investigational Cyclizine The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine. Approved Cyclopenthiazide The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclopenthiazide. Experimental Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pentazocine. Approved Cyclopropane The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclopropane. Experimental Cyclothiazide The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclothiazide. Approved Cyproheptadine The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyproheptadine. Approved Dantrolene The risk or severity of adverse effects can be increased when Pentazocine is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Pentazocine is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dapoxetine is combined with Pentazocine. Investigational Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine. Approved, Investigational Deramciclane The risk or severity of adverse effects can be increased when Pentazocine is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Pentazocine is combined with Desflurane. Approved Desipramine The risk or severity of adverse effects can be increased when Pentazocine is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Pentazocine. Approved, Investigational Desmopressin The risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin. Approved Desvenlafaxine Pentazocine may increase the serotonergic activities of Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Pentazocine is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine. Approved Dexetimide The risk or severity of adverse effects can be increased when Dexetimide is combined with Pentazocine. Withdrawn Dexmedetomidine The risk or severity of adverse effects can be increased when Pentazocine is combined with Dexmedetomidine. Approved, Vet Approved Dextroamphetamine Dextroamphetamine may increase the analgesic activities of Pentazocine. Approved, Illicit Dextromoramide Pentazocine may decrease the analgesic activities of Dextromoramide. Experimental, Illicit Dextropropoxyphene Pentazocine may decrease the analgesic activities of Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine Pentazocine may decrease the analgesic activities of Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Diazepam. Approved, Illicit, Investigational, Vet Approved Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine. Approved Diethyl ether The risk or severity of adverse effects can be increased when Pentazocine is combined with Diethyl ether. Experimental Diethylpropion Diethylpropion may increase the analgesic activities of Pentazocine. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Pentazocine is combined with Difenoxin. Approved, Illicit Dihydrocodeine Pentazocine may decrease the analgesic activities of Dihydrocodeine. Approved, Illicit Dihydroetorphine Pentazocine may decrease the analgesic activities of Dihydroetorphine. Experimental, Illicit Dihydromorphine Pentazocine may decrease the analgesic activities of Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Pentazocine is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Pentazocine is combined with Diphenhydramine. Approved, Investigational Diphenoxylate Pentazocine may decrease the analgesic activities of Diphenoxylate. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Pentazocine is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Pentazocine is combined with Doxepin. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved, Vet Approved DPDPE Pentazocine may decrease the analgesic activities of DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved, Vet Approved Drospirenone The risk or severity of adverse effects can be increased when Pentazocine is combined with Drospirenone. Approved Drotebanol The risk or severity of adverse effects can be increased when Pentazocine is combined with Drotebanol. Experimental, Illicit Duloxetine Pentazocine may increase the serotonergic activities of Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Pentazocine is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Pentazocine is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Pentazocine is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Pentazocine is combined with Efavirenz. Approved, Investigational Efonidipine The risk or severity of adverse effects can be increased when Pentazocine is combined with Efonidipine. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Pentazocine is combined with Eltanolone. Investigational Eluxadoline Pentazocine may increase the constipating activities of Eluxadoline. Approved, Investigational Emepronium The risk or severity of adverse effects can be increased when Emepronium is combined with Pentazocine. Experimental Enflurane The risk or severity of adverse effects can be increased when Pentazocine is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Pentazocine is combined with Entacapone. Approved, Investigational Epitizide The risk or severity of adverse effects can be increased when Pentazocine is combined with Epitizide. Experimental Eplerenone The risk or severity of adverse effects can be increased when Pentazocine is combined with Eplerenone. Approved Escitalopram Pentazocine may increase the serotonergic activities of Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Pentazocine is combined with Estazolam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Pentazocine. Approved, Investigational Etacrynic acid The risk or severity of adverse effects can be increased when Pentazocine is combined with Etacrynic acid. Approved, Investigational Etanautine The risk or severity of adverse effects can be increased when Etanautine is combined with Pentazocine. Experimental Ethanol Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethopropazine The risk or severity of adverse effects can be increased when Ethopropazine is combined with Pentazocine. Approved Ethosuximide The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethotoin. Approved Ethoxzolamide The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethoxzolamide. Withdrawn Ethyl carbamate The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine Pentazocine may decrease the analgesic activities of Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Pentazocine is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Pentazocine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Pentazocine is combined with Etomidate. Approved Etoperidone Pentazocine may increase the serotonergic activities of Etoperidone. Withdrawn Etorphine Pentazocine may decrease the analgesic activities of Etorphine. Illicit, Vet Approved Etybenzatropine The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Pentazocine. Experimental Ezogabine The risk or severity of adverse effects can be increased when Pentazocine is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Pentazocine is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Pentazocine is combined with Fencamfamine. Approved, Illicit, Withdrawn Fenquizone The risk or severity of adverse effects can be increased when Pentazocine is combined with Fenquizone. Experimental Fentanyl Pentazocine may decrease the analgesic activities of Fentanyl. Approved, Illicit, Investigational, Vet Approved Fesoterodine The risk or severity of adverse effects can be increased when Fesoterodine is combined with Pentazocine. Approved Fexofenadine The risk or severity of adverse effects can be increased when Pentazocine is combined with Fexofenadine. Approved, Investigational Flavoxate The risk or severity of adverse effects can be increased when Flavoxate is combined with Pentazocine. Approved Flibanserin The risk or severity of adverse effects can be increased when Pentazocine is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Pentazocine is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Pentazocine is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Flunitrazepam. Approved, Illicit Fluoxetine Pentazocine may increase the serotonergic activities of Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Pentazocine is combined with Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Pentazocine. Approved Flurazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Flurazepam. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Pentazocine is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Pentazocine is combined with Fluticasone propionate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Pentazocine is combined with Fluvoxamine. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Pentazocine is combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Pentazocine is combined with Fospropofol. Approved, Illicit, Investigational Furazolidone The risk or severity of adverse effects can be increased when Pentazocine is combined with Furazolidone. Approved, Investigational, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Pentazocine is combined with Furosemide. Approved, Vet Approved Gabapentin The risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin Enacarbil. Approved, Investigational Gallamine The risk or severity of adverse effects can be increased when Gallamine is combined with Pentazocine. Experimental Gallamine Triethiodide The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pentazocine. Approved Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Pentazocine is combined with Gamma Hydroxybutyric Acid. Approved, Illicit, Investigational Gepefrine Gepefrine may increase the analgesic activities of Pentazocine. Experimental Gepirone The risk or severity of adverse effects can be increased when Pentazocine is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Pentazocine is combined with Glutethimide. Approved, Illicit Glycopyrronium The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pentazocine. Approved, Investigational, Vet Approved Guanfacine The risk or severity of adverse effects can be increased when Pentazocine is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Pentazocine. Approved Halothane The risk or severity of adverse effects can be increased when Pentazocine is combined with Halothane. Approved, Vet Approved Harmaline The risk or severity of adverse effects can be increased when Pentazocine is combined with Harmaline. Experimental Heroin Pentazocine may decrease the analgesic activities of Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Pentazocine is combined with Hexobarbital. Approved Homatropine The risk or severity of adverse effects can be increased when Homatropine is combined with Pentazocine. Approved Hydracarbazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Hydracarbazine. Experimental Hydrochlorothiazide The risk or severity of adverse effects can be increased when Pentazocine is combined with Hydrochlorothiazide. Approved, Vet Approved Hydrocodone Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydroflumethiazide The risk or severity of adverse effects can be increased when Pentazocine is combined with Hydroflumethiazide. Approved, Investigational Hydromorphone Pentazocine may decrease the analgesic activities of Hydromorphone. Approved, Illicit Hydroxyamphetamine Hydroxyamphetamine may increase the analgesic activities of Pentazocine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pentazocine. Approved Ibopamine The risk or severity of adverse effects can be increased when Pentazocine is combined with Ibopamine. Experimental Iloperidone The risk or severity of adverse effects can be increased when Pentazocine is combined with Iloperidone. Approved Imipramine The risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine. Approved Indalpine Pentazocine may increase the serotonergic activities of Indalpine. Investigational, Withdrawn Indapamide The risk or severity of adverse effects can be increased when Pentazocine is combined with Indapamide. Approved Indiplon The risk or severity of adverse effects can be increased when Pentazocine is combined with Indiplon. Investigational Iofetamine I-123 Iofetamine I-123 may increase the analgesic activities of Pentazocine. Approved Ipratropium The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentazocine. Approved Iproclozide The risk or severity of adverse effects can be increased when Pentazocine is combined with Iproclozide. Withdrawn Iproniazid The risk or severity of adverse effects can be increased when Pentazocine is combined with Iproniazid. Withdrawn Isocarboxazid The risk or severity of adverse effects can be increased when Pentazocine is combined with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Pentazocine is combined with Isoflurane. Approved, Vet Approved Isosorbide The risk or severity of adverse effects can be increased when Pentazocine is combined with Isosorbide. Approved, Investigational Ketamine The risk or severity of adverse effects can be increased when Pentazocine is combined with Ketamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Pentazocine is combined with Ketazolam. Approved Ketobemidone Pentazocine may decrease the analgesic activities of Ketobemidone. Approved, Investigational L-Tryptophan L-Tryptophan may increase the serotonergic activities of Pentazocine. Approved, Nutraceutical, Withdrawn Lamotrigine The risk or severity of adverse effects can be increased when Pentazocine is combined with Lamotrigine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Pentazocine is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Pentazocine is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Pentazocine is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Pentazocine is combined with Levodopa. Approved Levomethadyl Acetate Pentazocine may decrease the analgesic activities of Levomethadyl Acetate. Approved, Investigational Levomilnacipran Pentazocine may increase the serotonergic activities of Levomilnacipran. Approved, Investigational Levorphanol Pentazocine may decrease the analgesic activities of Levorphanol. Approved Lidocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Lidocaine. Approved, Vet Approved Lisdexamfetamine Lisdexamfetamine may increase the analgesic activities of Pentazocine. Approved, Investigational Lithium cation The risk or severity of adverse effects can be increased when Pentazocine is combined with Lithium. Experimental Lofentanil Pentazocine may decrease the analgesic activities of Lofentanil. Illicit Lofexidine The therapeutic efficacy of Pentazocine can be increased when used in combination with Lofexidine. Approved, Investigational Loprazolam The risk or severity of adverse effects can be increased when Pentazocine is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Pentazocine is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Pentazocine. Approved Lormetazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Pentazocine. Approved Lurasidone The risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Pentazocine can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Mannitol The risk or severity of adverse effects can be increased when Pentazocine is combined with Mannitol. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline. Approved, Investigational Mazaticol The risk or severity of adverse effects can be increased when Mazaticol is combined with Pentazocine. Experimental Mebanazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Mebanazine. Withdrawn Mebicar The risk or severity of adverse effects can be increased when Pentazocine is combined with Mebicar. Experimental Mebutizide The risk or severity of adverse effects can be increased when Pentazocine is combined with Mebutizide. Experimental Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine. Approved, Investigational Meclizine The risk or severity of adverse effects can be increased when Pentazocine is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Pentazocine is combined with Medetomidine. Vet Approved Mefruside The risk or severity of adverse effects can be increased when Pentazocine is combined with Mefruside. Experimental Melatonin The risk or severity of adverse effects can be increased when Pentazocine is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Pentazocine is combined with Melperone. Approved, Investigational Mephedrone Mephedrone may increase the analgesic activities of Pentazocine. Investigational Mephentermine Mephentermine may increase the analgesic activities of Pentazocine. Approved Mepivacaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine. Approved, Illicit Meptazinol Pentazocine may decrease the analgesic activities of Meptazinol. Experimental Mersalyl The risk or severity of adverse effects can be increased when Pentazocine is combined with Mersalyl. Approved Mesoridazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Pentazocine is combined with Metaxalone. Approved Methadone Pentazocine may decrease the analgesic activities of Methadone. Approved Methadyl Acetate Pentazocine may decrease the analgesic activities of Methadyl Acetate. Approved, Illicit Methamphetamine Methamphetamine may increase the analgesic activities of Pentazocine. Approved, Illicit Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Pentazocine. Approved, Investigational Methapyrilene The risk or severity of adverse effects can be increased when Pentazocine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Pentazocine is combined with Methaqualone. Illicit, Withdrawn Methazolamide The risk or severity of adverse effects can be increased when Pentazocine is combined with Methazolamide. Approved Methocarbamol The risk or severity of adverse effects can be increased when Pentazocine is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Pentazocine. Approved Methotrimeprazine Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Pentazocine is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methoxyphenamine Methoxyphenamine may increase the analgesic activities of Pentazocine. Experimental Methscopolamine The risk or severity of adverse effects can be increased when Methscopolamine is combined with Pentazocine. Approved Methsuximide The risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Pentazocine is combined with Methyclothiazide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Pentazocine is combined with Methylecgonine. Experimental Methylene blue The risk or severity of adverse effects can be increased when Pentazocine is combined with Methylene blue. Approved, Investigational Methylnaltrexone The risk or severity of adverse effects can be increased when Pentazocine is combined with Methylnaltrexone. Approved Methylphenobarbital The risk or severity of adverse effects can be increased when Pentazocine is combined with Methylphenobarbital. Approved Methylscopolamine bromide The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Pentazocine. Approved Meticrane The risk or severity of adverse effects can be increased when Pentazocine is combined with Meticrane. Experimental Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Pentazocine. Approved Metolazone The risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone. Approved Metyrosine Pentazocine may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam. Approved, Illicit Midomafetamine Midomafetamine may increase the analgesic activities of Pentazocine. Experimental, Illicit, Investigational Milnacipran Pentazocine may increase the serotonergic activities of Milnacipran. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Pentazocine is combined with Minaprine. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved, Investigational Mirtazapine Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved MMDA MMDA may increase the analgesic activities of Pentazocine. Experimental, Illicit Moclobemide The risk or severity of adverse effects can be increased when Pentazocine is combined with Moclobemide. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Pentazocine is combined with Molindone. Approved Moricizine Moricizine may increase the hypotensive activities of Pentazocine. Approved, Investigational, Withdrawn Morphine Pentazocine may decrease the analgesic activities of Morphine. Approved, Investigational Muzolimine The risk or severity of adverse effects can be increased when Pentazocine is combined with Muzolimine. Experimental Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved, Investigational Nalbuphine Pentazocine may decrease the analgesic activities of Nalbuphine. Approved Naloxegol The risk or severity of adverse effects can be increased when Pentazocine is combined with Naloxegol. Approved Naltrexone The therapeutic efficacy of Pentazocine can be decreased when used in combination with Naltrexone. Approved, Investigational, Vet Approved Nefazodone Pentazocine may increase the serotonergic activities of Nefazodone. Approved, Withdrawn Nialamide The risk or severity of adverse effects can be increased when Pentazocine is combined with Nialamide. Withdrawn Nicomorphine Pentazocine may decrease the analgesic activities of Nicomorphine. Experimental Nitrazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrazepam. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrous oxide. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Pentazocine is combined with Norflurane. Approved, Investigational Normethadone Pentazocine may decrease the analgesic activities of Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Pentazocine is combined with Nortriptyline. Approved Octamoxin The risk or severity of adverse effects can be increased when Pentazocine is combined with Octamoxin. Withdrawn Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Pentazocine is combined with Olopatadine. Approved Ondansetron The risk or severity of adverse effects can be increased when Pentazocine is combined with Ondansetron. Approved Opium Pentazocine may decrease the analgesic activities of Opium. Approved, Illicit Orphenadrine Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Pentazocine is combined with Osanetant. Investigational Otilonium The risk or severity of adverse effects can be increased when Otilonium is combined with Pentazocine. Experimental, Investigational Oxazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Oxazepam. Approved Oxitropium The risk or severity of adverse effects can be increased when Oxitropium is combined with Pentazocine. Investigational Oxprenolol The risk or severity of adverse effects can be increased when Pentazocine is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Oxybuprocaine. Approved, Investigational Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentazocine. Approved, Investigational Oxycodone Pentazocine may decrease the analgesic activities of Oxycodone. Approved, Illicit, Investigational Oxymorphone Pentazocine may decrease the analgesic activities of Oxymorphone. Approved, Investigational, Vet Approved Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pentazocine. Approved Paliperidone The risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone. Approved Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Pentazocine. Approved Paraldehyde Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Pargyline The risk or severity of adverse effects can be increased when Pentazocine is combined with Pargyline. Approved Paroxetine Pentazocine may increase the serotonergic activities of Paroxetine. Approved, Investigational Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine. Approved Penfluridol The risk or severity of adverse effects can be increased when Pentazocine is combined with Penfluridol. Experimental Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Pentazocine. Approved, Investigational, Vet Approved Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Pentazocine. Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved Perazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Pentazocine is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Perphenazine. Approved Pethidine Pentazocine may decrease the analgesic activities of Pethidine. Approved Phenazocine Pentazocine may decrease the analgesic activities of Phenazocine. Experimental Phenelzine The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenelzine. Approved Phenglutarimide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Pentazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenibut. Experimental Pheniprazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Pheniprazine. Withdrawn Phenobarbital The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenobarbital. Approved, Investigational Phenoperidine Pentazocine may decrease the analgesic activities of Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenoxyethanol. Approved Phenoxypropazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenoxypropazine. Withdrawn Phentermine Phentermine may increase the analgesic activities of Pentazocine. Approved, Illicit Phenytoin The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pentazocine is combined with Pimozide. Approved Pipamperone The risk or severity of adverse effects can be increased when Pentazocine is combined with Pipamperone. Approved, Investigational Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Pentazocine. Approved Pipotiazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Pipotiazine. Approved, Investigational Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentazocine. Approved Piretanide The risk or severity of adverse effects can be increased when Pentazocine is combined with Piretanide. Approved Piritramide Pentazocine may decrease the analgesic activities of Piritramide. Approved, Investigational Pirlindole The risk or severity of adverse effects can be increased when Pentazocine is combined with Pirlindole. Approved Pivhydrazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Pivhydrazine. Withdrawn Pizotifen The risk or severity of adverse effects can be increased when Pentazocine is combined with Pizotifen. Approved Polythiazide The risk or severity of adverse effects can be increased when Pentazocine is combined with Polythiazide. Approved Pomalidomide The risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide. Approved Potassium cation The risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium. Approved, Investigational Potassium Citrate The risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium Citrate. Approved, Investigational, Vet Approved Pramipexole Pentazocine may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Pentazocine can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Prilocaine. Approved Primidone The risk or severity of adverse effects can be increased when Pentazocine is combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Procaine. Approved, Investigational, Vet Approved Procarbazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Procarbazine. Approved, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pentazocine. Approved, Vet Approved Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Pentazocine. Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Pentazocine. Approved, Vet Approved Promethazine Promethazine may increase the hypotensive activities of Pentazocine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Pentazocine is combined with Propanidid. Experimental Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Pentazocine. Approved Proparacaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Proparacaine. Approved, Vet Approved Propericiazine Propericiazine may increase the hypotensive activities of Pentazocine. Approved, Investigational Propiopromazine Propiopromazine may increase the hypotensive activities of Pentazocine. Vet Approved Propiverine The risk or severity of adverse effects can be increased when Propiverine is combined with Pentazocine. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Pentazocine is combined with Propofol. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Pentazocine is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Pentazocine is combined with PSD502. Investigational Pseudoephedrine Pseudoephedrine may increase the analgesic activities of Pentazocine. Approved Quazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Quazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Pentazocine is combined with Quetiapine. Approved Quinethazone The risk or severity of adverse effects can be increased when Pentazocine is combined with Quinethazone. Approved Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Pentazocine. Approved, Investigational Quinisocaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Pentazocine is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Pentazocine is combined with Ramelteon. Approved, Investigational Ramosetron Pentazocine may increase the constipating activities of Ramosetron. Approved, Investigational Rasagiline The risk or severity of adverse effects can be increased when Pentazocine is combined with Rasagiline. Approved Remifentanil Pentazocine may decrease the analgesic activities of Remifentanil. Approved Remoxipride The risk or severity of adverse effects can be increased when Pentazocine is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Pentazocine. Approved, Investigational Rilpivirine The serum concentration of Pentazocine can be decreased when it is combined with Rilpivirine. Approved Risperidone The risk or severity of adverse effects can be increased when Pentazocine is combined with Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Pentazocine is combined with Ritanserin. Investigational Ritobegron Ritobegron may increase the analgesic activities of Pentazocine. Investigational Rolofylline The risk or severity of adverse effects can be increased when Pentazocine is combined with Rolofylline. Investigational Romifidine The risk or severity of adverse effects can be increased when Pentazocine is combined with Romifidine. Vet Approved Ropinirole Pentazocine may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Ropivacaine. Approved Rotigotine Pentazocine may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Pentazocine. Approved Safrazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Safrazine. Withdrawn Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Pentazocine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Pentazocine. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Pentazocine is combined with Selegiline. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Pentazocine is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Pentazocine is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline Pentazocine may increase the serotonergic activities of Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Pentazocine is combined with Sevoflurane. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved Solifenacin The risk or severity of adverse effects can be increased when Solifenacin is combined with Pentazocine. Approved Spiradoline The risk or severity of adverse effects can be increased when Pentazocine is combined with Spiradoline. Investigational Spironolactone The risk or severity of adverse effects can be increased when Pentazocine is combined with Spironolactone. Approved Stiripentol The risk or severity of adverse effects can be increased when Pentazocine is combined with Stiripentol. Approved Succinylcholine Succinylcholine may increase the bradycardic activities of Pentazocine. Approved Sufentanil Pentazocine may decrease the analgesic activities of Sufentanil. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Pentazocine is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Pentazocine is combined with Sultopride. Experimental Suvorexant Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Pentazocine is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Pentazocine is combined with Tasimelteon. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Pentazocine. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Pentazocine is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrodotoxin. Investigational Thalidomide Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theobromine The risk or severity of adverse effects can be increased when Pentazocine is combined with Theobromine. Approved, Investigational Thiamylal The risk or severity of adverse effects can be increased when Pentazocine is combined with Thiamylal. Approved, Vet Approved Thiazinam Thiazinam may increase the hypotensive activities of Pentazocine. Experimental Thiethylperazine Thiethylperazine may increase the hypotensive activities of Pentazocine. Withdrawn Thiopental The risk or severity of adverse effects can be increased when Pentazocine is combined with Thiopental. Approved, Vet Approved Thioproperazine Thioproperazine may increase the hypotensive activities of Pentazocine. Approved Thioridazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Thioridazine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Pentazocine is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Pentazocine is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Pentazocine is combined with Tiapride. Approved, Investigational Ticrynafen The risk or severity of adverse effects can be increased when Pentazocine is combined with Ticrynafen. Withdrawn Tiletamine The risk or severity of adverse effects can be increased when Pentazocine is combined with Tiletamine. Vet Approved Tilidine Pentazocine may decrease the analgesic activities of Tilidine. Experimental Tiotropium The risk or severity of adverse effects can be increased when Tiotropium is combined with Pentazocine. Approved Tizanidine The risk or severity of adverse effects can be increased when Pentazocine is combined with Tizanidine. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Pentazocine is combined with Tolcapone. Approved, Withdrawn Toloxatone The risk or severity of adverse effects can be increased when Pentazocine is combined with Toloxatone. Approved Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Pentazocine. Approved, Investigational Tolvaptan The risk or severity of adverse effects can be increased when Pentazocine is combined with Tolvaptan. Approved Topiramate The risk or severity of adverse effects can be increased when Pentazocine is combined with Topiramate. Approved Torasemide The risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide. Approved Tramadol Pentazocine may decrease the analgesic activities of Tramadol. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Pentazocine is combined with Trazodone. Approved, Investigational Triamterene The risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene. Approved Triazolam The risk or severity of adverse effects can be increased when Pentazocine is combined with Triazolam. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Pentazocine is combined with Tricaine methanesulfonate. Vet Approved Trichlormethiazide The risk or severity of adverse effects can be increased when Pentazocine is combined with Trichlormethiazide. Approved, Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Pentazocine is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluoperazine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Triflupromazine. Approved, Vet Approved Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pentazocine. Approved Trimethaphan The risk or severity of adverse effects can be increased when Trimethaphan is combined with Pentazocine. Approved, Investigational Trimipramine The risk or severity of adverse effects can be increased when Pentazocine is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Pentazocine is combined with Triprolidine. Approved Tropatepine The risk or severity of adverse effects can be increased when Tropatepine is combined with Pentazocine. Experimental Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Pentazocine. Approved, Investigational Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Pentazocine. Approved Tubocurarine The risk or severity of adverse effects can be increased when Tubocurarine is combined with Pentazocine. Approved Ularitide The risk or severity of adverse effects can be increased when Pentazocine is combined with Ularitide. Investigational Umeclidinium The risk or severity of adverse effects can be increased when Umeclidinium is combined with Pentazocine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Pentazocine is combined with Valproic Acid. Approved, Investigational Vecuronium The risk or severity of adverse effects can be increased when Vecuronium is combined with Pentazocine. Approved Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pentazocine. Approved Venlafaxine Pentazocine may increase the serotonergic activities of Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Pentazocine is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Pentazocine is combined with Vigabatrin. Approved Vinyl ether The risk or severity of adverse effects can be increased when Pentazocine is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Pentazocine is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Pentazocine is combined with Xenon. Experimental Xipamide The risk or severity of adverse effects can be increased when Pentazocine is combined with Xipamide. Experimental Xylazine The risk or severity of adverse effects can be increased when Pentazocine is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Pentazocine is combined with Zaleplon. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Pentazocine is combined with Ziconotide. Approved Zimelidine Pentazocine may increase the serotonergic activities of Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine. Approved Zolazepam The risk or severity of adverse effects can be increased when Pentazocine is combined with Zolazepam. Vet Approved Zolpidem Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Pentazocine is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Pentazocine is combined with Zopiclone. Approved Zotepine The risk or severity of adverse effects can be increased when Pentazocine is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Pentazocine is combined with Zuclopenthixol. Approved, Investigational - Food Interactions
- Take without regard to meals. Avoid alcohol.
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014790
- KEGG Drug
- D00498
- KEGG Compound
- C07421
- PubChem Compound
- 441278
- PubChem Substance
- 46506363
- ChemSpider
- 390041
- BindingDB
- 50001028
- ChEBI
- 7982
- ChEMBL
- CHEMBL560
- Therapeutic Targets Database
- DAP000356
- PharmGKB
- PA164744326
- IUPHAR
- 1606
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Pentazocine
- ATC Codes
- N02AD01 — Pentazocine
- AHFS Codes
- 28:08.12 — Opiate Partial Agonists
- MSDS
- Download (48.4 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Treatment of Menopausal Hot Flashes 1 2 Completed Treatment Bipolar Disorder (BD) 1 2 Completed Treatment Bipolar Disorder (BD) / Mania / Manic Disorder / Manic syndromes / Schizoaffective Disorders 1 4 Unknown Status Treatment Anaesthesia therapy / Pregnancy Termination 1 Not Available Completed Treatment Headaches / Migraines 1
Pharmacoeconomics
- Manufacturers
- Sanofi aventis us llc
- Hospira inc
- Packagers
- A-S Medication Solutions LLC
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Hospira Inc.
- Kaiser Foundation Hospital
- Keltman Pharmaceuticals Inc.
- Mallinckrodt Inc.
- Nucare Pharmaceuticals Inc.
- Ohm Laboratories Inc.
- PD-Rx Pharmaceuticals Inc.
- Pharmedix
- Physicians Total Care Inc.
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Sanofi-Aventis Inc.
- Southwood Pharmaceuticals
- Stat Rx Usa
- Watson Pharmaceuticals
- Dosage forms
Form Route Strength Tablet Oral Injection, solution Intramuscular; Intravenous; Subcutaneous 30 mg/mL Solution Intramuscular; Intravenous; Subcutaneous 30 mg Tablet Oral 50 mg Liquid Intramuscular; Intravenous; Subcutaneous 30 mg - Prices
Unit description Cost Unit Talwin 30 mg/ml vial 14.78USD ml Talwin 30 mg/ml ampul 4.86USD ml Talwin 30 mg/ml 1.64USD ml Talwin 50 mg Tablet 0.47USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 146.3 °C PhysProp logP 4.64 DAYLIGHT (1999) pKa 8.88 SANGSTER (1994) - Predicted Properties
Property Value Source Water Solubility 0.122 mg/mL ALOGPS logP 4.44 ALOGPS logP 3.89 ChemAxon logS -3.4 ALOGPS pKa (Strongest Acidic) 7.59 ChemAxon pKa (Strongest Basic) 12.4 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 23.47 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 89.8 m3·mol-1 ChemAxon Polarizability 33.86 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9931 Blood Brain Barrier + 0.9769 Caco-2 permeable + 0.7902 P-glycoprotein substrate Substrate 0.9014 P-glycoprotein inhibitor I Inhibitor 0.8563 P-glycoprotein inhibitor II Inhibitor 0.6975 Renal organic cation transporter Inhibitor 0.6982 CYP450 2C9 substrate Non-substrate 0.7947 CYP450 2D6 substrate Substrate 0.8919 CYP450 3A4 substrate Substrate 0.7819 CYP450 1A2 substrate Inhibitor 0.5886 CYP450 2C9 inhibitor Non-inhibitor 0.8321 CYP450 2D6 inhibitor Inhibitor 0.8147 CYP450 2C19 inhibitor Non-inhibitor 0.8585 CYP450 3A4 inhibitor Non-inhibitor 0.8155 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.778 Ames test Non AMES toxic 0.8231 Carcinogenicity Non-carcinogens 0.9322 Biodegradation Not ready biodegradable 0.9888 Rat acute toxicity 2.4411 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.6301 hERG inhibition (predictor II) Inhibitor 0.5
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 2,6-dimethyl-3-benzazocines. These are aromatic compounds containing a 6,7-benzomorphan skeleton, which is substituted by methyl group at the 2- and 6-positions.
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- 6,7-benzomorphans
- Sub Class
- 2,6-dimethyl-3-benzazocines
- Direct Parent
- 2,6-dimethyl-3-benzazocines
- Alternative Parents
- 4-hydroxy-6,7-benzomorphans / Benzazocines / Tetralins / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds show 1 more
- Substituents
- 2,6-dimethyl-3-benzazocine / 4-hydroxy-6,7-benzomorphan / Benzazocine / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Benzenoid / Tertiary amine / Tertiary aliphatic amine show 10 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- benzazocine (CHEBI:7982)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
- Gene Name
- OPRM1
- Uniprot ID
- P35372
- Uniprot Name
- Mu-type opioid receptor
- Molecular Weight
- 44778.855 Da
References
- Levine JD, Gordon NC: Synergism between the analgesic actions of morphine and pentazocine. Pain. 1988 Jun;33(3):369-72. [PubMed:3419842]
- Martin BR, Katzen JS, Woods JA, Tripathi HL, Harris LS, May EL: Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther. 1984 Dec;231(3):539-44. [PubMed:6094791]
- Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y: Effects of diabetes on the antinociceptive effect of (+/-)pentazocine in mice. Res Commun Chem Pathol Pharmacol. 1994 Apr;84(1):105-10. [PubMed:8042002]
- Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334]
- Saha N, Datta H, Sharma PL: Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. Indian J Physiol Pharmacol. 1990 Jul;34(3):179-82. [PubMed:2286420]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Opioid receptor activity
- Specific Function
- G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
- Gene Name
- OPRK1
- Uniprot ID
- P41145
- Uniprot Name
- Kappa-type opioid receptor
- Molecular Weight
- 42644.665 Da
References
- Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Opioid receptor activity
- Specific Function
- Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma m...
- Gene Name
- SIGMAR1
- Uniprot ID
- Q99720
- Uniprot Name
- Sigma non-opioid intracellular receptor 1
- Molecular Weight
- 25127.52 Da
References
- Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445]
- Colabufo NA, Contino M, Inglese C, Niso M, Perrone R, Roperto S, Roperto F: In vitro and ex vivo characterization of sigma-1 and sigma-2 receptors: agonists and antagonists in biological assays. Cent Nerv Syst Agents Med Chem. 2009 Sep;9(3):161-71. [PubMed:20021350]
- Dun Y, Thangaraju M, Prasad P, Ganapathy V, Smith SB: Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1 specific ligand. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4785-94. [PubMed:17898305]
- Mamolo MG, Zampieri D, Zanette C, Florio C, Collina S, Urbano M, Azzolina O, Vio L: Substituted benzylaminoalkylindoles with preference for the sigma2 binding site. Eur J Med Chem. 2008 Oct;43(10):2073-81. Epub 2007 Sep 26. [PubMed:18069094]
- Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, Mavlyutov T, Ruoho AE: Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol. 2007 Oct;72(4):921-33. Epub 2007 Jul 10. [PubMed:17622576]
Drug created on June 13, 2005 07:24 / Updated on July 22, 2018 19:28